Fintel on MSN
Truist Securities initiates coverage of Maze Therapeutics (MAZE) with buy recommendation
Fintel reports that on March 18, 2026, Truist Securities initiated coverage of Maze Therapeutics (NasdaqGM:MAZE) with a Buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results